Alexander Spira, MD, PhD | Authors


The Safety Profile of Amivantamab and Lazertinib in EGFR-Mutant NSCLC

June 06, 2021

Alexander Spira, MD, PhD, FACP, director of the Virginia Cancer Specialists Research Institute, discusses the safety profile of amivantamab and lazertinib in EGFR-mutated non-small cell lung cancer, based on data from the CHRYSALIS tria.

PACIFIC Regimen Is Appropriate for Use in Patients With Non–Small Cell Lung Cancer After Chemoradiation

April 17, 2021

During a virtual Targeted Oncology Case-Based Roundtable event, Alexander Spira, MD, PhD, discusses when the use of durvalumab followed by chemoradiotherapy is appropriate for patients with unresectable stage III non–small cell lung cancer.